Tango Therapeutics

About Tango Therapeutics

Tango Therapeutics develops targeted cancer treatments using the principle of synthetic lethality, which allows them to design drugs that kill cancer cells while leaving healthy cells unharmed. Their approach focuses on the interaction between genes, where the loss of both genes leads to cell death, but the loss of only one does not. This method enables them to create therapies that are more precise in targeting tumors. Tango operates in the oncology market, primarily serving healthcare providers and pharmaceutical companies interested in advanced cancer therapies. They collaborate with larger pharmaceutical firms, like Gilead Sciences, to co-develop their treatments, which helps in funding and speeding up the process of bringing these drugs to market. Tango's goal is to advance their pipeline of targeted immunotherapies through strong research and development efforts and strategic partnerships.